Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients with advanced relapsed or refractory lymphoma.
Presentation details are as follows:
Presenter: Krish Patel, MD
Title: Ongoing, First-in-human, Phase 1 Dose Escalation Study of the Investigational CD47-blocker TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma
Session: Developmental Therapeutics - Immunotherapy
Abstract: 3030
Session Type: Poster Presentation (Poster #94)
The poster will be available on the meeting website beginning Friday, May 29 at 8:00 am ET. A copy of the poster will also be available on the Events and Presentations page of Trillium’s website.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Company Contact:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
